Wave Life Sciences Ltd. Q2 2025 Earnings Recap

WVE Q2 2025 August 1, 2025

Get alerts when WVE reports next quarter

Wave Life Sciences reported strong advancements in its RNA medicine pipeline during Q2 2025, highlighted by successful clinical progress in both AATD and obesity programs, positioning the company for significant upcoming data releases.

Earnings Per Share Miss

$-0.31 vs $-0.29 est.

-6.9% surprise

Revenue Miss

8699000 vs 9850000 est.

-11.7% surprise

Market Reaction

1-Day +1.39%

5-Day -5.79%

30-Day +17.61%

See WVE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Successful initiation and rapid advancement of the INLIGHT clinical program for obesity, with safety and tolerability data supporting dose escalation.
Positive proof of mechanism results from the FORWARD-53 trial of N531 for Duchenne muscular dystrophy, showcasing the strength of Wave's RNA editing technology.
Continued momentum in the AATD clinical program with promising durability data from WVE-006, indicating potential for extended dosing intervals and positive patient outcomes.
Strengthened leadership with the addition of Dr. Chris Wright as Chief Medical Officer, enhancing expertise in regulatory and therapeutic development.
Anticipation for multiple impactful data releases in Q3 2025, catalyzing investor interest and informing future pipeline directions.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit WVE on AllInvestView.

Next Q3 2025